What is Tevimbra (Tislelizumab-jsgr)?

Tevimbra (Tislelizumab-jsgr) is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody indicated for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma who have received prior systemic chemotherapy without a PD-(L)1 inhibitor. Esophageal squamous cell carcinoma (ESCC) is a cancer that occurs in the epithelial cells of the upper esophagus. This is the most common form of esophageal cancer.

Tevimbra is a PD-1 antibody with high affinity and binding specificity for PD-1, a protein found on immune T cells. When proteins on cancer cells bind to the PD-1 receptor on T cells, the T cells are inactivated, which prevents them from killing cancer cells. Tevimbra works by blocking PD-1 so T cells remain active and increases the T cells' ability to kill cancer cells. Tevimbra also minimizes binding to Fc-gamma (Fcγ) receptors, a potential mechanism of anti-PD-1 resistance.

Tevimbra is administered by intravenous infusion every 3 weeks. The first infusion is administered over 60 minutes, but subsequent infusions can be administered over 30 minutes if tolerated. Common adverse reactions include anemia, fatigue, musculoskeletal pain, weight loss, and cough. Common laboratory abnormalities include increased glucose, decreased hemoglobin, lymphopenia, decreased sodium, decreased albumin, increased alkaline phosphatase, and increased AST.

Warnings and precautions related toTevimbra include immune-mediated adverse reactions, infusion-related reactions, complications of allogeneic hematopoietic stem cell transplantation (HSCT), and embryo-fetal toxicity.

Reference: https://www.drugs.com/history/tevimbra.html